Said Akli

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cell Cycle 11:1468-76. 2012
  2. pmc Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors
    Said Akli
    Departments of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1179-90. 2010
  3. pmc Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells
    Mylinh T Duong
    Departments of Experimental Radiation Oncology, Radiation Oncology, and Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0066, Houston, TX77030, USA
    Cancer Res 73:5556-68. 2013
  4. ncbi request reprint Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:3198-208. 2004
  5. pmc Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:188-91. 2004
  6. pmc LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients
    Mylinh T Duong
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS Genet 8:e1002538. 2012
  7. ncbi request reprint Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy
    Said Akli
    Department of Experimental Radiation Oncology UT MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer Biol Ther 2:S38-47. 2003
  8. pmc Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E
    Said Akli
    Department of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, TX, USA
    Cancer Res 71:3377-86. 2011
  9. ncbi request reprint Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:7212-22. 2007
  10. ncbi request reprint Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer
    Michelle Craig Barton
    Department of Biochemistry and Molecular Biology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cell Physiol 209:686-94. 2006

Collaborators

Detail Information

Publications11

  1. pmc Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cell Cycle 11:1468-76. 2012
    ..031) and invasiveness (p = 0.021) of the bladder tumors and poor overall survival (p = 0.06). These results suggest that LMW cyclin E can be used as a new prognostic marker for bladder cancer...
  2. pmc Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors
    Said Akli
    Departments of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1179-90. 2010
    ....
  3. pmc Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells
    Mylinh T Duong
    Departments of Experimental Radiation Oncology, Radiation Oncology, and Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0066, Houston, TX77030, USA
    Cancer Res 73:5556-68. 2013
    ..Collectively, our results suggest that the heightened oncogenecity of LMW-E relates to its ability to promote CSC properties, supporting the design of therapeutic strategies to target this unique function...
  4. ncbi request reprint Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:3198-208. 2004
    ....
  5. pmc Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:188-91. 2004
    ..These findings suggest that high levels of LMW isoforms of cyclin E not only can predict failure to endocrine therapy but also are true prognostic indicators because of their influence on cell proliferation and genetic instability...
  6. pmc LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients
    Mylinh T Duong
    Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS Genet 8:e1002538. 2012
    ..The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib...
  7. ncbi request reprint Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy
    Said Akli
    Department of Experimental Radiation Oncology UT MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer Biol Ther 2:S38-47. 2003
    ....
  8. pmc Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E
    Said Akli
    Department of Experimental Radiation Oncology, University of Texas, MD Anderson Cancer Center, TX, USA
    Cancer Res 71:3377-86. 2011
    ..Our findings establish a requirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, arguing that human breast tumors overexpressing LMW-cyclin E are prime candidates for anti-Cdk2 therapy...
  9. ncbi request reprint Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway
    Said Akli
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:7212-22. 2007
    ..Therefore, LMW cyclin E overexpression strongly selects for spontaneous inactivation of the ARF-p53 pathway in vivo, canceling its protective checkpoint function and accelerating progression to malignancy...
  10. ncbi request reprint Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer
    Michelle Craig Barton
    Department of Biochemistry and Molecular Biology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cell Physiol 209:686-94. 2006
    ..To determine how this escape hatch is opened and, ultimately, how to close it, we must understand the networks of normal signaling and processing in a cell and where they intersect...
  11. ncbi request reprint The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells
    Hannah Wingate
    Department of Experimental Radiation Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cell Cycle 2:461-6. 2003
    ..These results suggest that overexpression of the LMW forms of cyclin E is mitogenic, stimulating the cells to progress through the cell cycle much more efficiently than the full length cyclin E...